No Data
No Data
Beijing Wantai Biological Pharmacy Enterprise 2024 Semi-Annual Report.
Summary of Beijing Wantai Biological Pharmacy Enterprise's 2024 half-year report
Behind the "cliff-like" decline in performance of Beijing Wantai Biological: vaccine business revenue decreased by more than 80% | interpretations
①The main reason for the significant decline in the performance of beijing wantai biological pharmacy enterprise's H1 is the decrease in sales revenue of the bivalent HPV vaccine. ②The revenue of the company's diagnostic division exceeded the vaccine division, while overseas revenue saw a certain year-on-year growth. ③The production conditions for the commercialization of the nonavalent HPV vaccine of the company are in place, and the listing application is progressing according to plan.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): the nine-valent HPV vaccine is expected to be included in the priority review program.
On August 12th, Gelunhui reported that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd. collaborated with Xiamen University to research and develop a nine-valent vaccine (Escherichia coli) for human papillomavirus type 6/11/16/18/31/33/45/52/58 (referred to as 'nine-valent HPV vaccine'), which is on the priority list of drugs for review and approval by the National Medical Products Administration's drug evaluation center, with a public notice period of 7 days.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): There is still a significant gap in the supply of global HPV vaccines.
On August 9th, Gluonpli reported that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on its interactive platform that, based on the World Health Organization's global strategy for accelerating the elimination of cervical cancer, it is expected that the demand for routine HPV vaccine administration globally will reach 0.1 billion doses/year in 2024, increasing annually and maintaining at 0.12 billion doses / year. At present, there is still a significant gap in the supply of global HPV vaccines. In order to make up for this gap, the company actively expands the international market, and has obtained market approvals in more than ten countries; at the same time, it actively responds to international organizations such as WHO, the Gates Foundation, PATH, UNICEF, PAHO, GAVI, etc.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): spent a total of 101 million yuan to repurchase 0.1285% of the shares.
On August 1st, Gelunhui reported that, as of July 31, 2024, Beijing Wantai Biological Pharmacy Enterprise (603392.SH) had repurchased 1,629,585 shares of stock through centralized bidding, accounting for 0.1285% of the company's total share capital. The highest repurchase price was 74.48 yuan/share, the lowest was 45.55 yuan/share, and the total amount paid for the repurchase was RMB 0.101 billion yuan (excluding trading commissions and other fees).
No Data